Onconova Therapeutics, a clinical-stage biopharmaceutical company, has its sights set on developing innovative products for cancer treatment in the United States. Currently boasting two clinical-stage programs, including the Phase I narazaciclib study for solid tumors and hematological malignancies as a single agent or with other anti-cancer therapies, as well as the Phase I/IIa study of oral rigosertib alone and in combination with PD-1 inhibitor for progressive K-Ras mutated non-small cell lung cancer, Onconova Therapeutics is keen on making substantial strides in the fight against cancer. The company is also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced and metastatic squamous cell carcinoma complemented with recessive dystrophic epidermolysis bullosa. To further its efforts, Onconova Therapeutics has a license and collaboration agreement with HanX Biopharmaceuticals for narazaciclib registration, development, and commercialization in China. Onconova Therapeutics was established in 1998 and has its base in Newtown, Pennslyvania.